Kraig Biocraft Laboratories(KBLB)
$0.08+0.00 (+1.23%)
KBLB
Kraig Biocraft Laboratories financials statements
$0.08
At close:+0.00 (+1.23%)
Kraig Biocraft Laboratories (KBLB) Ratios
130 Followers
Kraig Biocraft Laboratories Ratios
KBLB's free cash flow for Q2 2026 was $-627.30K. For the 2026 fiscal year, KBLB's free cash flow was decreased by $-28.61K and operating cash flow was $-598.70K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.18 | 0.00 | 0.29 | 0.49 | 0.29 |
| Quick Ratio | 0.18 | 0.00 | 0.29 | 0.49 | 0.29 |
| Cash Ratio | 0.17 | 0.00 | 0.29 | 0.48 | 0.29 |
| Solvency Ratio | -0.34 | -0.35 | -0.34 | -0.47 | -0.96 |
| Operating Cash Flow Ratio | -0.17 | -0.00 | -0.14 | -0.23 | -0.22 |
| Short-Term Operating Cash Flow Coverage | -1.20 | -1.14 | -0.75 | -1.10 | -0.81 |
| Net Current Asset Value | $ -8.70M | $ -8.91M | $ -6.37M | $ -4.11M | $ -5.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.65 | 1.13 | 0.54 | 0.39 | 0.80 |
| Debt-to-Equity Ratio | -0.21 | -0.21 | -0.31 | -0.50 | -0.46 |
| Debt-to-Capital Ratio | -0.26 | -0.26 | -0.44 | -1.01 | -0.84 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| Financial Leverage Ratio | -0.32 | -0.18 | -0.57 | -1.30 | -0.57 |
| Debt Service Coverage Ratio | -1.47 | 0.00 | -1.21 | -0.90 | -0.92 |
| Interest Coverage Ratio | -5.91 | 0.00 | -5.40 | -3.48 | -4.18 |
| Debt to Market Cap | 0.02 | 0.02 | 0.04 | 0.06 | 0.03 |
| Interest Debt Per Share | 0.00 | -510.03 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.04 | -0.36 | 0.31 | 1.00 | -0.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 107.37% | 110.53% | 115.87% | 181.14% | 291.52% |
| Return on Assets (ROA) | -141.23% | -225.80% | -93.73% | -84.05% | -266.26% |
| Return on Equity (ROE) | 45.30% | 41.71% | 53.09% | 109.09% | 151.93% |
| Return on Capital Employed (ROCE) | 42.83% | 0.00% | 46.26% | 60.58% | 53.69% |
| Return on Invested Capital (ROIC) | 53.27% | 0.00% | 66.06% | 121.22% | 95.98% |
| Return on Tangible Assets | -141.23% | -225.80% | -93.73% | -84.05% | -266.26% |
| Earnings Yield | -4.00% | -3.53% | -7.58% | -12.72% | -11.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.05 | 0.05 | 0.05 | 0.05 | 6265.80 |
| Inventory Turnover | 0.86 | 3.80 | 4.01 | 4.27 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6918.97 | -6908.42 | -7066.79 | -6932.43 | -0.06 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 422.47 | 96.05 | 90.97 | 85.46 | 0.00 |
| Days of Payables Outstanding | 7341.44 | 7004.47 | 7157.77 | 7017.89 | 0.06 |
| Operating Cycle | 422.47 | 96.05 | 90.97 | 85.46 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -331.60 | -433.75 | -194.48 | -375.86 | -18.54 |
| Capital Expenditure Coverage Ratio | -331.60 | -433.75 | -194.48 | -375.86 | -18.54 |
| Operating Cash Flow Coverage Ratio | -1.08 | -1.08 | -0.71 | -1.06 | -0.74 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -1.98% | -1.91% | -3.13% | -6.26% | -2.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -25.15 | -28.11 | -13.20 | -7.86 | -8.73 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -11.32 | -11.82 | -7.01 | -8.58 | -13.26 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -50.48 | -52.25 | -31.97 | -15.96 | -36.99 |
| Price-to-Operating Cash Flow Ratio | -50.64 | -52.37 | -32.13 | -16.00 | -38.99 |
| Price-to-Earnings Growth (PEG) Ratio | -8.30 | -2.04 | 0.51 | 0.13 | -0.15 |
| Enterprise Value Multiple | -29.88 | -34.24 | -15.15 | -13.43 | -26.46 |
| Enterprise Value | 90.46M | 97.34M | 39.19M | 28.11M | 70.27M |
| EV to EBITDA | -29.88 | -34.24 | -15.15 | -13.43 | -26.46 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -50.41 | -52.81 | -31.33 | -14.86 | -37.03 |
| EV to Operating Cash Flow | -50.56 | -52.93 | -31.49 | -14.90 | -39.02 |
| Tangible Book Value Per Share | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 |
| Shareholders’ Equity Per Share | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.19 | 1.18 | 1.16 | 1.81 | 3.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.49 | 0.54 | 0.41 | 0.49 | 0.22 |
Currency in USD
